Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit. The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs. Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way. They expect significant manufacturing increases to occur, starting in the back half of the year. CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.” Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter. |
Turkey halts all trade with Israel over military actions in GazaBeijing gears up for Strawberry Music Festival during May Day holidayAI data training supported by domestic chips, supercomputersBeijing International Film Festival opens for cultural dialoguesA scroll for the king, a website for the people: Coronation document to be released digitallyMan arrested in fatal shooting of Chicago police officer who was heading home from workWarriors executive Onsi Saleh joins Hawks front office at assistant GMChina's new energy competitiveness honed through genuine expertiseMike Yaz homers at Fenway after visit from Hall of Fame grandfather; Giants beat Red Sox 3Marlins slip past Rockies 5